Stock Market & Financial Investment News

Imperva sell-off overdone, says Sterne AgeeAfter Imperva expanded its 2014 revenue guidance, Sterne Agee expects the top end of the guidance to reach 20% in 2015. The firm expects the company's sales execution issues to be resolved, and it keeps a Buy rating on the shares.

Imperva revenue growth set to rebound, says OppenheimerAfter meeting with Imperva's management, Oppenheimer says that the company's focus on salesforce best practices and its good execution should cause its revenue growth to accelerate. The firm adds that demand for the company's products is strong, and it keeps a $55 price target and Outperform rating on the shares.